PROVECA LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +12.5%

  £15,455,702 → £17,391,974

• Cash

  +18.1%

  £4,125,584 → £4,871,983

  highest in 5 filed years

• Net assets

  -303.7%

  -£704,628 → -£2,844,391

• Employees

  +13.8%

  65 → 74

  highest in 5 filed years

• Operating profit

  -46.9%

  -£993,492 → -£1,458,987

• Profit before tax

  -34.9%

  -£1,381,305 → -£1,862,976

• Wages

  -0.2%

  £5,857,963 → £5,845,977

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Forvis Mazars LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors believe the Group will have adequate resources available to continue to operate for more than a year after the date of signing of these accounts and the Directors continue to adopt the going concern basis of accounting in preparing the financial statements.”

Group structure

1. PROVECA LIMITED · parent
   1. Proveca Pharma Limited 100% · Ireland · research, development and manufacture of pharmaceutical preparations
   2. Proveca (Germany) GmbH 100% · Germany · research, development and manufacture of pharmaceutical preparations
   3. Proveca Italy SRL 100% · Italy · research, development and manufacture of pharmaceutical preparations
   4. Proveca (France) SAS 100% · France · research, development and manufacture of pharmaceutical preparations

Significant events

• “In September 2024, we established our 5th Proveca group company in France, supporting improved patient access to our products following successful reimbursement negotiations for Sialanar.”
• “Subsequent to the reporting date, Proveca Pharma Limited, a subsidiary of Proveca Limited, made the decision to terminate a licensing arrangement following continued unfavourable regulatory, pricing, and commercial developments in the relevant markets. As a result, management determined that the related intangible asset and associated inventory would not generate future economic benefits and therefore require full impairment.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

1

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.